Matt Riley | Head, IR |
Al Altomari | Chairman and CEO |
Amy Welsh | VP, Marketing |
Oren Livnat | H.C. Wainright |
Good afternoon, and welcome to the Agile Therapeutics Second Quarter 2022 Financial Results Conference Call. Please note, today's event is being recorded. I would now like to turn the conference over to Matt Riley, Head of Investor Relations.
Hello, everyone, and welcome to today's conference call to discuss our second quarter 2022 financial results and corporate update.
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook and financing prospects for the future, our outlook for the second half of 2022, management's expectations for our future financial and operational performance, including our expectations regarding the market growth of Twirla, our business strategy, our partnership with Afaxys and its ability to promote growth, our product supply agreement with Nurx and its ability to educate patients about Twirla, our connected TV campaign and its ability to promote growth and our assessment of the combined hormonal contraceptive market in general, among other statements regarding our plans, prospects and expectations.